| Property | Value |
|---|
|
?:abstract
|
-
As a result of the rapid spread of COVID-19 and turning into a pandemic the deterioration of the condition of many people and the increase of deaths, caused the need for urgent treatment There is no drug and/or vaccine approved by the health authorities for treatment because it is the first time the disease is encountered The existing drugs are medicines used for other known indications in the treatment to relieve the symptoms and slow the progression of the disease This situation causes data insufficiency in the drugs and treatment approaches used and/or intended to be used, as well as insufficient data on the disease In this review article, it is aimed to evaluate the biopharmaceutics and pharmacokinetics properties, treatment applications and clinical researches, generic drug development and patent status of the drugs used in COVID-19 treatment protocols in Turkey and worldwide, with current data
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Biopharmaceutics, pharmacokinetics and patent evaluations of drugs used in the treatment of COVID-19: Current status in the development of generic drugs in Turkey
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}